Top Ranked Momentum Stocks to Buy for February 21st
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:
CNA Financial Corporation (CNA): This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
CNA Financial Corporation Price and Consensus
CNA Financial Corporation price-consensus-chart | CNA Financial Corporation Quote
CNA Financial’s shares gained 10% over the last one month above the S&P 500’s increase of 1.6%. The company possesses a Momentum Score of A.
CNA Financial Corporation Price
CNA Financial Corporation price | CNA Financial Corporation Quote
Electromed, Inc. (ELMD): This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Electromed, Inc. Price and Consensus
Electromed, Inc. price-consensus-chart | Electromed, Inc. Quote
Electromed’s shares gained 21.1% over the last one month. The company possesses a Momentum Score of A.
Electromed, Inc. Price
Electromed, Inc. price | Electromed, Inc. Quote
Pacira BioSciences, Inc. (PCRX): This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.
Pacira Pharmaceuticals, Inc. Price and Consensus
Pacira Pharmaceuticals, Inc. price-consensus-chart | Pacira Pharmaceuticals, Inc. Quote
Pacira BioSciences’ shares gained 12.4% over the last one month. The company possesses a Momentum Score of A.
Pacira Pharmaceuticals, Inc. Price
Pacira Pharmaceuticals, Inc. price | Pacira Pharmaceuticals, Inc. Quote
Regeneron Pharmaceuticals, Inc. (REGN): This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Regeneron Pharmaceuticals, Inc. price-consensus-chart | Regeneron Pharmaceuticals, Inc. Quote
Regeneron Pharmaceuticals’ shares gained 9.7% over the last one month. The company possesses a Momentum Score of A.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. price | Regeneron Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Pacira Pharmaceuticals, Inc. (PCRX) : Free Stock Analysis Report
Electromed, Inc. (ELMD) : Free Stock Analysis Report
CNA Financial Corporation (CNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research